Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030

Immune Checkpoint Inhibitors - Market Insights, Competitive Landscape, and Market Forecast - 2030

Immune Checkpoint Inhibitors Market By Type (Pd-1 Inhibitors, Pd-L1 Inhibitors, Ctla-4 Inhibitors, And Lag-3 Inhibitors), Application (Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing cases of lung cancer and the rising prevalence of melanoma

The global Immune Checkpoint Inhibitors Market was valued at USD 41.65 billion in 2023, growing at a CAGR of 14.55% during the forecast period from 2024 to 2030 to reach USD 107.37 billion by 2030. The demand for Immune Checkpoint Inhibitors is primarily being boosted owing to the increasing cases of lung cancer, the rising prevalence of melanoma, and the rising number of research studies associated with immune checkpoint inhibitors, among others during the forecast period from 2024 to 2030.

Immune Checkpoint Inhibitors Market Dynamics:

The increasing number of lung cancer cases is one of the key drivers that will raise the demand for immune checkpoint inhibitors treatment and lead to an increase in the immune checkpoint inhibitors market growth in the upcoming years.

For instance, the International Agency for Research on Cancer (IARC) (2022), stated that there were 20 million new cancer cases in 2020 globally, with 1 in 9 men and 1 in 12 women expected to die from cancer. The source further stated that lung cancer and female breast cancer were the most commonly occurring cancers in 2022 worldwide, accounting respectively for 12.4% and 11.6% of total new cases; followed by colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%). Therefore, owing to an increase in the number of patients suffering from various types of cancers and the deaths associated with it, there will be an increase in the demand for immune checkpoint inhibitors, thus spurring their market growth during the forecast period.

Furthermore, as per the American Cancer Society’s statistics for lung cancer in the United States (2022), about 236,740 new cases of lung cancer were observed in the year 2022.

Moreover, as per Cancer Research UK 2022, there are about 48,500 new lung cancer cases in the United Kingdom on average every year, which accounts for more than 130 cases per day. Also, as per the same source, lung cancer is the third most common cancer in the United Kingdom, thereby accounting for more than 13% of all new cancer cases.

The immune checkpoint inhibitors allow the immune system to recognize and attack the cancer cells. Owing to a rise in the number of patients suffering from lung cancers, there will be an increase in the demand for immune checkpoint inhibitors, leading to an increase in the overall immune checkpoint inhibitors market growth.

However, the high cost associated with the research and development of immune checkpoint inhibitors, and the regulatory price capping pertaining to them may act as significant restraints that are expected to limit the growth of the Immune Checkpoint Inhibitors market during the forecast period.

Immune Checkpoint Inhibitors Market Segment Analysis:

Immune Checkpoint Inhibitors Market by Type (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, and LAG-3 Inhibitors), Application (Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the Immune Checkpoint Inhibitors market, the PD-1 Inhibitors category is estimated to amass a significant revenue share in the Immune Checkpoint Inhibitors market in 2023. This can be ascribed to the various advantages associated with them and the product development activities taking place in the PD-1 Inhibitors category.

PD-1 inhibitor is a checkpoint protein on immune cells called the T cells. The monoclonal antibodies target either PD-1 or PD-L1 and block the binding and helps in boosting the immune response against the cancer cells.

The upsurge in cancer cases across the globe will drive the demand for PD-1 inhibitors. For instance, As per the data from GLOBOCAN (2022) over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022, with the proportional increase in incidence most striking in low Human Development Index (HDI) countries (142% increase) and in medium HDI countries (99%). The source also stated that cancer mortality in these countries is projected to almost double in 2050. These drugs can be used in the treatment of several forms of cancer.

For instance, several PD-1 inhibitor drugs that have been approved by the Food and Administration approval comprise pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Therefore, the rising prevalence of cancer and the increased FDA approval of PD-1 inhibitors are the prime factors expected to drive the growth of the immune checkpoint inhibitors market over the forecast episode.

Hence, all the aforementioned factors will contribute to the growth of the Immune Checkpoint Inhibitors market for PD-1 inhibitors during the forecast period from 2024 to 2030.

North America Is Expected To Dominate The Overall Immune Checkpoint Inhibitors Market:

North America is expected to account for the highest proportion of the Immune Checkpoint Inhibitors market in 2023, out of all regions. This is owing to the rising prevalence of cancers such as bladder cancer, lung cancer, and others in the region. In addition, rising product approvals, growing focus on R&D activities by the key manufacturers, and rising government initiatives in the region are the factors responsible for the growth of the North America immune checkpoint inhibitors market.

For instance, as per the Centers for Disease Control and Prevention (CDC) (2022), each year in the United States, about 54,000 men and 16,000 women get bladder cancer on average.

In addition, as per the American Cancer Society 2023, approximately 82,290 new cases of bladder cancer (about 62,420 in men and 19,870 in women) were diagnosed in 2023 in the US. The source further mentioned that around 97,610 new melanomas were diagnosed (about 58,120 in men and 39,490 in women) in the US in 2023.

The rising approval of immune checkpoint inhibitors by the FDA is also responsible for increasing the demand for immune checkpoint inhibitors leading to the overall market growth.

For example, pembrolizumab (Keytruda), ipilimumab (Yervoy), nivolumab (Opdivo), and atezolizumab (Tecentriq) have been approved by the FDA authority for the treatment of various cancers.

Thus, all the above-mentioned factors are anticipated to propel the market for Immune Checkpoint Inhibitors in North America during the forecast period from 2024 to 2030.

Immune Checkpoint Inhibitors Market Key Players:

Some of the key market players operating in the Immune Checkpoint Inhibitors market include F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co., AstraZeneca Plc., Merck & Co., Inc., Sanofi, Regeneron, GSK plc., EMD Serono, Jiangsu Hengrui Medicine, BeiGene Ltd, Junshi Biosciences, and others.

Recent Developmental Activities In The Immune Checkpoint Inhibitors Market:

In March 2023, BioNTech SE and OncoC4, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologicals for cancer treatment, announced that they entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.

In March 2022, Bristol Myers Squibb announced that Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

In October 2020, CStone Pharmaceuticals announced an agreement to out-license ex-Greater China rights for two key late-stage immuno-oncology assets, sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1), to EQRx, a biopharmaceutical company with an innovative business model that allowed these drugs to be competitively positioned in global markets against established treatments for the target indications.

Key Takeaways From The Immune Checkpoint Inhibitors Market Report Study

Market size analysis for current Immune Checkpoint Inhibitors Market size (2023), and market forecast for 6 years (2024 to 2030)

Top key offerings, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global Immune Checkpoint Inhibitors market.

Various opportunities available for the other competitors in the Immune Checkpoint Inhibitors Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Immune Checkpoint Inhibitors market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Immune Checkpoint Inhibitors market growth in the coming future?

Target Audience Who Can Be Benefited From This Immune Checkpoint Inhibitors Market Report Study

Immune Checkpoint Inhibitor providers

Public and Private Corporate companies

Immune Checkpoint Inhibitors-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Providers dealing in Immune Checkpoint Inhibitors

Various corporates who want to know more about the Immune Checkpoint Inhibitors Market and the latest offerings in the Immune Checkpoint Inhibitors Market.

Frequently Asked Questions For The Immune Checkpoint Inhibitors Market:

1. What are Immune Checkpoint Inhibitors?

Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.

2. What is the market for Immune Checkpoint Inhibitors?

The global Immune Checkpoint Inhibitors Market was valued at USD 41.65 billion in 2023, growing at a CAGR of 14.55% during the forecast period from 2024 to 2030 to reach USD 107.37 billion by 2030.

3. What are the drivers for the Global Immune Checkpoint Inhibitors market?

The Immune Checkpoint Inhibitors Market is slated to witness prosperity owing to the increasing cases of lung cancer, the rising prevalence of melanoma, and the rising number of research studies associated with immune checkpoint inhibitors, among others during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global Immune Checkpoint Inhibitors market?

Some of the key market players operating in the Immune Checkpoint Inhibitors market include F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co., AstraZeneca Plc., Merck & Co., Inc., Sanofi, Regeneron, GSK plc., EMD Serono, Jiangsu Hengrui Medicine, BeiGene Ltd, Junshi Biosciences, and others.

5. Which region has the highest share in the Global Immune Checkpoint Inhibitors market?

North America is expected to dominate the overall Immune Checkpoint Inhibitors market during the forecast period from 2024 to 2030. This is owing to the rising prevalence of cancers such as bladder cancer, lung cancer, and others in the region. In addition, rising product approvals, growing focus on R&D activities by the key manufacturers, and rising government initiatives in the region are the factors responsible for the growth of the North America immune checkpoint inhibitors market.